Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Mendus, Audiocast, Q3'25

By Inderes11/13/2025, 1:00 PM
Mendus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Eric
00:01 - 03:41

Good afternoon, everybody. Good morning. For those of you from the US joining, welcome to the Q3 financial and business update from Mendus AB Public Company. We have to show our disclaimer. It's also available on our website. The Q3 of 2025 has mainly been focusing on the progress in myeloid cancers. It means we have followed up our ADVANCE II Phase 2A trial and have demonstrated a positive outcome now at 48 months median follow-up. But also, these data give us a lot of confidence about the potential of the product in the broader AML setting. We have started, and the trial is ongoing and recruiting the AML 22 CADENCE trial, together with the Australasian Leukaemia and Lymphoma Group, in short, the CADENCE trial. And this is a phase two combination trial with a drug approved for AML patients who have been treated with high-intensity chemotherapy, called oral azacitidine. The trial is gaining momentum, and we have set a goal to enroll 20 patients by the first quarter of 2026, after which we will also prepare an initial readout. Another important step is that the AML first-line treatment landscape is evolving, and we have to adapt to that. So next to high-intensity chemotherapy, there is now a very successful regimen of two drugs called venetoclax and azacitidine, used as a means to get chemo-ineligible AML patients into complete remission. And that is a growing patient population which is also in very high need of post-remission immunotherapy. And we want to be part of that transformation of the AML landscape. So we are now preparing with Andrew Way, the same professor who is also heading the AMLM22-CADENCE Ph 2b trial, a trial called Diva, which is a phase one trial to study Vididencel in combination with Azacitidine and Venetoclax for the first time. Also, importantly, as a very attractive market segment in myeloid blood cancers, we have decided to position vididencel in chronic myeloid leukemia. We will share a few details about the background of that new indication in the upcoming slides. But also importantly, we have already prepared in detail the trials to enter into this field with the phase one and phase two, a trial scheduled to start in 2026. Mid this year, we announced that the United States Patent and Trademark Office (USPTO) granted a US patent covering the use of vididencel in ovarian cancer. That's part of an ongoing trial. The ALISON trial is in phase one. But this also validates the use of the product in ovarian cancer. And it gives us an excellent opportunity to see how the ALISON trial plays out. And, of course, this effectively protects our product specifically for use in that indication. Then we have a platform that we have been developing; a lot of pre-clinical research has been going on in our labs. We have made the pre-clinical research subject to partnering. And we actually also announced in the third quarter that we have closed an initial partnership with an international biopharmaceutical company in a research collaboration with our lab.

Unknown 1
03:42 - 04:37

Yes, please. Hi, everyone. There isn't much to say about the financials, as usual. We have an operating result of 20.44 million. The negative cash flow is 21.4. So it's more or less in line with the result. And it depends. And it's because we have now entered a late-stage phase with Norflex. So then we don't have costs every month because the cost for the batches will come when they are delivered to us. The cash position at the end of Q3 is 37.6 million. And we expect that to result in having a cash runway into the beginning of 2026.

Eric
04:39 - 17:40

Thank you very much. Then, as a high-level summary of why we are in AML, AML is a very aggressive tumor with immunotherapy essentially being the only chance of cure. The only approved immunotherapy currently in AML is bone marrow transplant or hematopoietic stem cell transplant. Also, in short, HSCT. This is a very high-risk procedure which is inaccessible to most AML patients without a transplant. AML patients face imminent relapse due to residual disease, and actually, the five-year survival rate for AML has been dramatically low, well below 30%. Why are we relevant? We offer a safe immunotherapy to reduce relapse by providing immune control over the residual disease. We have shown that this leads to durable clinical remissions. But also, very importantly, our product is safe. So we preserve health and quality of life for the patients treated. This is the 48-month data that I alluded to. What you see is a nice plateau. It means that after the initial patients who failed to respond to the therapy suffered from relapse. You see a relatively large population responding with long-term survival. And that is the plateau. So, the flattening of the curve that you see when you go to the right-hand side indicates that a number of patients have already passed the five-year survival mark. So, this is a very striking result. As you know from our previous presentations, we have also looked in a lot of detail into the immune system of the patients. And we could show that all the patients with a reasonable immune system at the start of treatment were able to build up immune responses against leukemic antigens after treatment with Vididencel. And also all of them became long-term survivors. So the majority of patients are still alive at 48 months. Median follow-up. And that is a great outcome. So that gives us the confidence that we can push vididencel in the broader setting in AML. And this is an overview of the AML treatment landscape. Again, HSCT is still the only curative approach, but for the many patients not able to undergo HSCT, there are actually two solutions: one is oral ASA, but oral ASA or oral azacitidine is not very effective. It does give some progression-free survival benefit, but when you look at long-term overall survival, it has very limited effect. And it's still below 30%. So that patient population is the one we are currently treating in the CADENCE trial. And then at the bottom, you see the patient population which is currently classified as chemo-unfit. So these patients do not receive the classical high intensity chemotherapy. But the combination of azacitidine and venetoclax. But there is no transplant option. So the need for immunotherapy to ensure these patients don't relapse is actually even larger than in the chemo-eligible patient population. So this is the reason, plus the fact that the treatment is so effective, it's being used more and more as a first-line treatment, even for patients that are classically classified as chemo fit, means that this is a very fast-growing patient population in need of post-remission immunotherapy. And this is why we want to expand the positioning of vididencel with the trial, which is a phase one trial addressing azacitidine and treated patients. Overall, the time to market has not changed significantly from our earlier plans, which were to execute a more narrowly defined trial with Oral azacitidine in only MRD positive patients. There are two reasons why we have adjusted the strategy. First of all, the developments in the AML landscape and the growing opportunity for post-remission immunotherapy are significant factors. So we want to make sure that we adjust to that evolving landscape and are optimally positioned for vididencel in terms of reaching the market and also the overall market potential. So we have to adapt the execution of a clinical trial to align with the developments in the field, and additionally, the use of MRD has evolved. So where MRD was not part of our phase one trial because it was not commonly used in clinical practice. In our phase two trial, the ADVANCE II trial we just looked at, we could use it to stratify patients into MRD positive, being a high-risk patient population. But nowadays MRD is used much more continuously to monitor disease. And there's also a variation in MRD levels depending on how the disease is monitored. There are different techniques to do it. In a nutshell, MRD is a very important parameter and part of AML treatment, but the use of it has become a lot more diverse and continuous, rather than just a black and white classification of MRD positive and negative patients. So all in all, we want to first move beyond MRD positive patients. That is what's currently going on in the CADENCE trial because we treat both positive and negative patients and then assess the patient population very quickly. A growing patient population in need of post-remission immunotherapy is, in principle, also not eligible for transplant. So there is an even higher unmet medical need. And we really want to ensure that we capture the broader AML opportunity. And also ensuring that our plans to go to market with this product have the best chances of reaching the market, along with securing the recruitment needed to support the phase three trial in the best possible way. So the overall timelines to get to market, we estimate, are not significantly different from the originally planned time to market. We just optimize the chances of getting there. Then of course, we've had an end-of-phase two meeting with the FDA. We are also preparing for large-scale GMP production. We have a manufacturing alliance with a company called North Biologics. We have entered into the production phase of that alliance, so we are currently evaluating the batches that we have manufactured. And of course, as soon as we can confirm that we have successfully manufactured and released those batches, we will also notify the market. But the alliance is on track and a very important part of supporting the late-stage development of vididencel and AML. Then I will spend a little bit more time on the CML field. And the reason is it's a new field that we aim to enter. Acute myeloid leukemia and chronic myeloid leukemia do share antigens. That is well documented. But also we have done some pre-clinical work ourselves that we presented last year at the ASH conference, showing that Vididencel actually stimulates immune cells to build up immunity against CML, which is, of course, a starting point for an active immunotherapy to accomplish immune control over the residual disease. But why is it so relevant in CML? CML is a disease that is driven by a specific oncogene called BCR-ABL. And because this oncogene is so specific, it can also be effectively controlled with inhibitors, Abl1 tyrosine kinase inhibitors, or TKIs. It means that the disease is, in principle, under control, and that treatment focus has shifted from short-term disease control to quality of life and cost reduction. The quality of life is heavily affected by lifelong TKI usage, so patients really want to try and stop their TKIs, and that is called a treatment-free remission, which has become a key therapy goal in CML. However, if you need to put pressure on the disease with TKIs and you stop using them, in a lot of patients, it quite quickly leads to rising levels of disease within the first 6 to 12 months. In that situation, patients have to be put back on the original or a new generation of TKIs. And the limited success of treatment-free remission (TFR) is basically still an unresolved question. So going back to immune control, CML before the invention of TKIs was treated with hematopoietic stem cell transplant. So with bone marrow transplants, because it's such a dangerous procedure, it's hardly used anymore. The other immune drug that has been tried in CML is interferon alpha. But also, it is a very difficult drug to use due to its toxicity and challenging therapeutic window. So people are really looking for new immune therapies to improve TFR success, to ensure that the immune system can control residual disease and that you don't need to take your TKIs for the rest of your life. Now that is a significant unmet medical need. Also, when you look into the patient numbers on the right-hand side, you will appreciate that CML is a much larger field than AML. And the main reason is that CML patients live longer. So it's a growing patient population. The estimated numbers now are roughly 150,000 patients in Europe and 150,000 in the US, so adding up to roughly 300,000 patients in Europe and the US alone. And almost all these patients have one single goal, which is to live a healthy life without being committed to lifelong drug usage. What we will try to accomplish in 2026 is, first of all, ensuring safety and identifying early signs of efficacy based on the molecular levels of disease that we can monitor. Then, quite quickly, we plan to step up and start a phase two trial after the initial phase one safety readout. And we will focus in that phase on patients who have previously failed a TFR attempt. The reason to do that is that the failure rate in the first year, at the first TFR attempt, and this is for patients who have had very stable, very low levels of disease allowing them to finally stop their TKIs, is 50%. So this is a good patient population to start and try to pick up the signal that immunotherapy like vididencel allows patients to have a better outcome of their TFR attempt. The start of both of these trials is planned for 2026. Then moving to the summary in the outlook. So the positive ADVANCE Phase II data that we have presented, with 48 months of median follow-up, shows that these patients have a chance of durable clinical remissions without having to pay a price of toxicity. The very safe treatment really boosts our confidence to position vididencel more broadly in the AML landscape. And we are currently doing this in the randomized control trial with oral azacitidine. But we will also expand to the chemo-unfit patient population in the trial, in combination with Azacitidine and Venetoclax. The clinical data we expect from both trials in 2026, plus the anticipated first-line treatment landscape in AML, will guide our optimal go-to-market strategy in AML. The indication expansion to CML, with a clear rationale based on a very large and growing patient population with unmet medical needs, will open up large additional market potential for vididencel in myeloid blood cancers. And we have already detailed the clinical trial strategy to advance that indication. Then I should also mention that in ovarian cancer, we have published positive data in the middle of this year at ASCO. And we will continue to follow up on these patients. We expect the next readout of the ovarian cancer trial before the year end. So as near-term clinical milestones, we have the continued long-term follow-up of the ADVANCE II trial, including an update before the year-end. We have the long-term follow-up data from the ALISON trial in ovarian cancer, and then in the expansion of the positioning of vididencel in the myeloid blood cancer space. We have a number of key readouts planned for 2026, including the CADENCE trial readout based on the first 20 patients in the trial. The trial readout based on initial safety and efficacy data, and the initial safety and feasibility data in CML, is, of course, the first big step into the remainder of the phase one trial, but also the start of the phase two trial. So with that, I would like to hand it over to the Q&A session and am welcome to answer any questions.

Operator
17:41 - 17:59

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the Pound Key on your telephone keypad. The next question comes from Christian Binder from Redeye. Please go ahead.

Christian Binder
18:01 - 18:19

Hi. Thanks so much for taking my question. I was wondering about potential late-stage development in AML. Previously, you've remarked that you could get to market with a relatively small phase three trial. Is it still the case, or would it potentially need to be expanded given the broader positioning?

Eric
18:21 - 19:24

Hi Christian, thanks for your question. Yeah, I think the short answer to your question is we will expect a somewhat larger patient population if we, let's say, broaden the addressable patient population post-chemotherapy. So, it also includes MRD-negative patients, who tend to experience a somewhat longer period before potential relapse. But the recruitment and, in the end, also the probability of success in running that trial will significantly improve because you, first of all, have a much broader patient population. So, we anticipate the trial to be larger. Initially, we said 150 to 200 patients. We now think that the registration trial in that setting will require around 250 patients. But the lack of complexity and a much broader patient population to be included will certainly facilitate the recruitment of that trial.

Christian Binder
19:26 - 19:29

All right. Perfect. That was all from my side. Thank you so much.

Eric
19:29 - 19:30

Thanks, Christian.

Operator
19:33 - 19:37

The next question comes from Aaron Achkar from Edison Group. Please go ahead.

Aaron Achkar
19:40 - 19:53

Hi there, Eric. Nice to see the presentation. Thanks for taking my questions. The first one I've got is, could you provide some more detail on the trial design, size, and endpoints that might be used for this phase one trial?

Eric
19:56 - 20:21

Yes, absolutely. It's going to be a typical phase one trial. Aaron. And we anticipate enrolling 24 patients within 12 months. This is a much more prevalent patient population. We think, therefore, that we can run a relatively quick trial with the initial safety and feasibility signal already established in 2026. However, the trial will, of course, extend into 2027.

Aaron Achkar
20:24 - 20:40

Okay. So, if I'm understanding correctly. So there will be 24 patients over 12 months, and the initial readout would be in mid 2026. So will that interim sort of readout be? An interim readout will not correspond to the full results. Is that right?

Eric
20:40 - 21:00

Exactly like in phase one for CML. You know, in the first eight patients, you want to establish safety and feasibility, and safety, of course, is clearly monitored on a day-to-day basis in all of our trials. But feasibility will also involve determining if we can detect some initial molecular responses at the disease level.

Aaron Achkar
21:02 - 21:21

And yes, we think, therefore, that we can run a relatively quick trial with the initial safety and feasibility signal already established in 2026. Thank you. And then my next question, looking at the CML details in a bit more depth. So assuming the phase one trial is successful, for the planned phase two trial, am I right in thinking that vididencel will be evaluated as a monotherapy? And are there any more details you can provide on the design and whether it will be self-sponsored?

Eric
21:23 - 23:01

Yes. So apart from whether the trials are company-sponsored or investigator-sponsored because that question is always a matter of the financials involved, but also the need for certain coordination in the execution. I think the centers we work with in Australia, and as you know, the center running or coordinating the CADENCE trial is run by Andrew Wei. That's an investigator-sponsored trial. The same applies to the trial, which will also be led by Professor Wei. These are very experienced clinical centers that also have all of the infrastructure to monitor these trials. So there, you don't have to step in as a company. And the same is true for the phase two trial, which will be supervised by Professor Timothy Hughes, who is also a very renowned collaborator. These groups know what to do. So in principle, we don't need to step in as a company. And those will be investigator-sponsored trials. The phase one in CML is a new indication, and we want to have a little bit more control over it. We will work. So it will be a corporate-sponsored trial, but we will work with the group at Bergen University, led by Professor Brian Geertsen, who was also kind enough to give an interview for the Q3 report. And he is very experienced with the product because he's also been part of our AML trial. So everything is in close coordination with the investigators, but with some nuances regarding whether it's a corporate or an investigator-sponsored trial.

Aaron Achkar
23:03 - 23:11

And he is very experienced with the product because he's also been part of our AML trial. Thank you. And sorry, just in case I missed it, is the phase two design still to be determined in terms of size and endpoints?

Eric
23:11 - 24:39

Yes, that's correct. Sorry, I forgot to answer that part of the question. Sorry. Well, the idea, I will describe it in a little bit more detail. There are basically two main issues with TFR and CML. First of all, you are formally only eligible for a TFR attempt as a patient if you've had very deep and consistent responses. On TKIs, a lot of patients don't reach that point. So that's called suboptimal responders. That is a patient population that we will enrich for in the phase one trial to see whether we can already make a difference or observe a change in the patients who have difficulties reaching those very deep molecular responses on TKIs only. So the phase one will be a combination trial. In the phase two trial, we will focus on patients that have achieved those deep molecular responses. But the expectation is that as soon as they stop their TKI, the probability of rising disease levels is very high. So that's a different trial. And that is where you start the treatment of vididencel while the patients are still on TKI. Then you stop the treatment to see whether there is an improved outcome of that TFR attempt, because the immune system must then essentially control the disease and hopefully prevent rising disease levels as soon as you stop the TKI. Does that answer your question?

Aaron Achkar
24:41 - 24:44

And he is very experienced with the product because he's also been part of our AML trial. That's super helpful. Thanks very much. No more from me.

Eric
24:44 - 24:45

Thanks, Eric.

Operator
24:48 - 25:04

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Eric
25:05 - 25:09

Thank you everybody for joining. Have a lovely day and speak to you soon.

Unknown 1
25:09 - 25:10

Yes. Thank you.

Eric
25:10 - 25:11

Thank you for attending the presentation. We look forward to keeping you updated on our progress. If you have any questions, please feel free to reach out to us.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…